Browse by People


Up a level
Export as [feed] RSS [feed] RSS 2.0 Short Author List
Number of items: 7.


Donovan-Banfield, I'ah ORCID: 0000-0002-5124-2427, Penrice-Randal, Rebekah ORCID: 0000-0002-0653-2097, Goldswain, Hannah ORCID: 0000-0003-4194-8714, Rzeszutek, Aleksandra M, Pilgrim, Jack, Bullock, Katie, Saunders, Geoffrey, Northey, Josh, Dong, Xiaofeng, Ryan, Yan ORCID: 0000-0002-4708-5350
et al (show 24 more authors) (2022) Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial. NATURE COMMUNICATIONS, 13 (1). 7284-.


Quinn, Leonard M, Haldenby, Sam, Antzcak, Philip, Fowler, Anna, Bullock, Katie ORCID: 0000-0002-5758-0179, Kenny, John, Gilbert, Timothy, Andrews, Timothy, Diaz-Nieto, Rafael, Fenwick, Stephen
et al (show 7 more authors) (2023) Genomic profiling of idiopathic peri-hilar cholangiocarcinoma reveals new targets and mutational pathways. Scientific Reports, 13 (1). 6681-.


Niemi, Mari EK, Karjalainen, Juha, Daly, Mark, Ganna, Andrea, Mehtonen, Juha, Cordioli, Mattia, Kaunisto, Mari, Pigazzini, Sara, Donner, Kati, Kivinen, Katja
et al (show 3481 more authors) (2021) Mapping the human genetic architecture of COVID-19. NATURE, 600 (7889). 472-+.


Khoo, Saye H ORCID: 0000-0002-2769-0967, FitzGerald, Richard, Saunders, Geoffrey, Middleton, Calley, Ahmad, Shazaad, Edwards, Christopher J, Hadjiyiannakis, Dennis, Walker, Lauren ORCID: 0000-0002-3827-4387, Lyon, Rebecca, Shaw, Victoria ORCID: 0000-0002-0429-0186
et al (show 80 more authors) (2022) Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial. The Lancet Infectious Diseases, 23 (2). pp. 183-195.


Khoo, Saye H ORCID: 0000-0002-2769-0967, Fitzgerald, Richard, Fletcher, Thomas, Ewings, Sean, Jaki, Thomas, Lyon, Rebecca, Downs, Nichola, Walker, Lauren ORCID: 0000-0002-3827-4387, Tansley-Hancock, Olana, Greenhalf, William
et al (show 28 more authors) (2021) Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76 (12). pp. 3286-3295.


FitzGerald, Richard, Dickinson, Laura ORCID: 0000-0001-5557-9396, Else, Laura, Fletcher, Thomas, Hale, Colin, Amara, Alieu ORCID: 0000-0002-1137-2948, Walker, Lauren ORCID: 0000-0002-3827-4387, Penchala, Sujan Dilly, Lyon, Rebecca, Shaw, Victoria ORCID: 0000-0002-0429-0186
et al (show 9 more authors) (2022) Pharmacokinetics of ss-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. CLINICAL INFECTIOUS DISEASES, 75 (1). E525-E528.


Relph, Katharine A, Russell, Clark D, Fairfield, Cameron J, Turtle, Lance, de Silva, Thushan I, Siggins, Matthew K, Drake, Thomas M, Thwaites, Ryan S, Abrams, Simon, Moore, Shona C
et al (show 358 more authors) (2022) Procalcitonin Is Not a Reliable Biomarker of Bacterial Coinfection in People With Coronavirus Disease 2019 Undergoing Microbiological Investigation at the Time of Hospital Admission. Open Forum Infectious Diseases, 9 (5). ofac179-.

This list was generated on Sun Apr 7 12:16:15 2024 BST.